Corteva 10-Q 2026-09-30
CTVA · CIK 1755672 · Form 10-Q · Period ended September 30, 2026 · Filed November 12, 2026
Revenue fell 6.1% to $2.46 billion. The net loss was $570 million.
8 sections, 430K characters. Original on sec.gov · ·
| Measure | Quarter ended Sep 30, 2026 | Quarter ended Sep 30, 2025 | Change |
|---|---|---|---|
| Revenue | $2.46B | $2.62B | -6.1% |
| Net income | -$570M | -$320M | n/a |
| Diluted EPS | -$0.85 | -$0.47 | n/a |
| Cash and equivalents | $3.93B | n/a | n/a |
From the XBRL facts tagged to this filing; both columns are as reported in this filing.
Cover and table of contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2026
OR
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ____________ to ____________
Commission File Number 001-38710
Corteva, Inc.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 82-4979096 | |||||||||||||||||||||||||
| (State or other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | |||||||||||||||||||||||||
| 9330 Zionsville Road, | Indianapolis, | Indiana | 46268 | (833) | 267-8382 | |||||||||||||||||||||
| 1000 N. West Street, Suite 900, | Wilmington, | Delaware | 19801 | |||||||||||||||||||||||
| (Address of Principal Executive Offices) (Zip Code) | (Registrant’s Telephone Number, including area code) |
Commission File Number 1-815
EIDP, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 51-0014090 | |||||||||||||||||||||||||
| (State or other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | |||||||||||||||||||||||||
| 9330 Zionsville Road, | Indianapolis, | Indiana | 46268 | (833) | 267-8382 | |||||||||||||||||||||
| 1000 N. West Street, Suite 900, | Wilmington, | Delaware | 19801 | |||||||||||||||||||||||
| (Address of Principal Executive Offices) (Zip Code) | (Registrant’s Telephone Number, including area code) |
Securities registered pursuant to Section 12(b) of the Act for Corteva, Inc.:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common Stock, par value $0.01 per share | CTVA | New York Stock Exchange |
Securities registered pursuant to Section 12(b) of the Act for EIDP, Inc.:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| $3.50 Series Preferred Stock | CTAPrA | New York Stock Exchange | ||||||
| $4.50 Series Preferred Stock | CTAPrB | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
| Corteva, Inc. | Yes | x | No | o | ||||||||||
| EIDP, Inc. | Yes | x | No | o |
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
| Corteva, Inc. | Yes | x | No | o | ||||||||||
| EIDP, Inc. | Yes | x | No | o |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Corteva, Inc. | Large Accelerated Filer | x | Accelerated Filer o | Non-Accelerated Filer | o | Smaller reporting company o | Emerging growth company o | ||||||||||||||||
| EIDP, Inc. | Large Accelerated Filer | o | Accelerated Filer o | Non-Accelerated Filer | x | Smaller reporting company o | Emerging growth company o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Corteva, Inc. | o | ||||
| EIDP, Inc. | o |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
| Corteva, Inc. | Yes | o | No | x | ||||||||||
| EIDP, Inc. | Yes | o | No | x |
Corteva, Inc. had 667,323,000 shares of common stock, par value $0.01 per share, outstanding at November 5, 2026.
EIDP, Inc. had 200 shares of common stock, par value $0.30 per share, outstanding at November 5, 2026, all of which are held by Corteva, Inc.
EIDP, Inc. meets the conditions set forth in General Instruction H(1)(a) and (b) of Form 10-Q (as modified by a grant of no-action relief dated February 12, 2018) and is therefore filing this form with reduced disclosure format.
Corteva, Inc.
EIDP, Inc.
Table of Contents
Explanatory Note
Corteva, Inc. owns all of the common equity interests in EIDP, Inc. EIDP, Inc. is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Securities Exchange Act of 1934, as amended.
Unless otherwise indicated or the context otherwise requires, references in this Quarterly Report on Form 10-Q to:
-
“Corteva” or “the company” refers to Corteva, Inc. and its consolidated subsidiaries (including EIDP);
-
“EIDP” refers to EIDP, Inc. (formerly known as E. I. du Pont de Nemours and Company) and its consolidated subsidiaries or EIDP, Inc. excluding its consolidated subsidiaries, as the context may indicate;
-
“DowDuPont” refers to DowDuPont Inc. and its subsidiaries prior to the Corteva Separation (defined below);
-
“Historical Dow” refers to The Dow Chemical Company and its consolidated subsidiaries prior to the Internal Reorganization (defined below);
-
“Historical DuPont” refers to EIDP prior to the Internal Reorganization (defined below);
-
“Internal Reorganizations” refers to the series of internal reorganization and realignment steps undertaken by Historical DuPont and Historical Dow to realign its business into three subgroups: agriculture, materials science and specialty products. Refer to the company’s Annual Report on Form 10-K for the year ended December 31, 2025 for further information.
-
“Dow Distribution” refers to the separation of DowDuPont’s materials science business into a separate and independent public company on April 1, 2019 by way of a distribution of Dow Inc. through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow Inc.’s common stock;
-
“Merger” refers to the all-stock merger of equals strategic combination between Historical Dow and Historical DuPont on August 31, 2017;
-
“Dow” refers to Dow Inc. after the Dow Distribution;
-
“DuPont” refers to DuPont de Nemours, Inc. after the Corteva Separation (on June 1, 2019, DowDuPont Inc. changed its registered name to DuPont de Nemours, Inc.);
-
“Corteva Separation” refers to June 1, 2019, when Corteva, Inc. became an independent, publicly traded company;
-
“Corteva Distribution” refers to the pro rata distribution of all of the then-issued and outstanding shares of Corteva, Inc.’s common stock on June 1, 2019, which was then a wholly-owned subsidiary of DowDuPont, to holders of DowDuPont’s common stock as of the close of business on May 24, 2019;
-
“Distributions” refers to the Dow Distribution and the Corteva Distribution;
-
“Letter Agreement” refers to the Letter Agreement executed by DuPont and Corteva on June 1, 2019, which sets forth certain additional terms and conditions related to the Corteva Separation, including certain limitations on each party’s ability to transfer certain businesses and assets to third parties without assigning certain of such party’s indemnification obligations under the Corteva Separation Agreement to the other party to the transferee of such businesses and assets or meeting certain other alternative conditions;
-
“Vylor” refers to Vylor Inc., the company’s historical Seed business and a wholly-owned subsidiary of EIDP that became an independent, publicly traded company on October 1, 2026;
-
“Vylor Separation” refers to October 1, 2026, when Vylor Inc. became an independent, publicly traded company;
-
“New Corteva” refers to the company’s historical Crop Protection business (inclusive of the historical Crop Protection business of EIDP);
-
“Seed Business” refers to the business, operations and activities of the Seed operating segment of Corteva; and
-
“Crop Protection Business” refers to the business, operations and activities of the Crop Protection operating segment of Corteva.
On October 1, 2026, Corteva, Inc. (“Corteva” or “the company”) completed its previously announced separation into two independent, publicly traded companies – one comprising its Crop Protection Business (“New Corteva” or the “Crop Protection Business”) and the other comprising its Seed Business (“Vylor”, “our,” “we,” or “the Seed Business”) – through a pro rata dividend in-kind of all of the then-issued and outstanding shares of common stock of Vylor to holders of Corteva’s common stock as of the close of business on September 24, 2026 (the “Vylor Separation”). The transaction was intended to be a tax-free spin-off for U.S. federal income tax purposes. In connection with the Vylor Separation, Vylor became an independent, publicly traded company and, effective October 1, 2026, New Corteva and Vylor are separate registrants. Irrespective of the legal form of the spin-off in which Vylor (inclusive of the Seed Business) is the legal spinnee in the transaction, Vylor is the accounting spinnor and, therefore, is the accounting successor to Corteva subsequent to the Vylor Separation. Vylor has been identified as the accounting spinnor given, among other factors, Vylor’s relative significance to New Corteva. The historical consolidated financial statements of Corteva are the historical financial statements of Vylor for the periods prior to the Vylor Separation, and the financial statements of the Crop Protection business will become the historical financial statements of Corteva.
This Quarterly Report on Form 10-Q is a combined report being filed separately by Corteva, Inc. and EIDP, Inc.. The information in this Quarterly Report on Form 10-Q is equally applicable to Corteva, Inc. and EIDP, Inc., except where otherwise indicated.
The separate EIDP, Inc. financial statements and footnotes for areas that differ from Corteva, Inc., are included within this Quarterly Report on Form 10-Q. Footnotes of EIDP, Inc. that are identical to that of Corteva, Inc. are cross-referenced accordingly.
This Quarterly Report on Form 10-Q contains historical Consolidated Financial Statements for Corteva as of September 30, 2026, December 31, 2025 and September 30, 2025, and for the three- and nine-month periods ended September 30, 2026 and 2025.
PART I. FINANCIAL INFORMATION
Item 1. CONSOLIDATED FINANCIAL STATEMENTS
Corteva, Inc.
Consolidated Statements of Operations (Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||
| (In millions, except per share amounts) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||
| Net sales | $ | 2,458 | $ | 2,618 | $ | 13,742 | $ | 13,491 | ||||||||||||
| Cost of goods sold | 1,534 | 1,644 | 6,624 | 6,918 | ||||||||||||||||
| Research and development expense | 397 | 351 | 1,126 | 1,061 | ||||||||||||||||
| Selling, general and administrative expenses | 732 | 725 | 2,773 | 2,632 | ||||||||||||||||
| Amortization of intangibles | 159 | 162 | 513 | 485 | ||||||||||||||||
| Restructuring and asset related charges - net | 17 | 30 | 158 | 131 | ||||||||||||||||
| Separation costs | 99 | 7 | 230 | 7 | ||||||||||||||||
| Other income (expense) - net | (34) | (23) | (266) | 95 | ||||||||||||||||
| Interest expense | 75 | 46 | 158 | 134 | ||||||||||||||||
| Income (loss) from continuing operations before income taxes | (589) | (370) | 1,894 | 2,218 | ||||||||||||||||
| Provision for (benefit from) income taxes on continuing operations | (62) | (62) | 479 | 477 | ||||||||||||||||
| Income (loss) from continuing operations after income taxes | (527) | (308) | 1,415 | 1,741 | ||||||||||||||||
| Income (loss) from discontinued operations after income taxes | (41) | (10) | (95) | (87) | ||||||||||||||||
| Net income (loss) | (568) | (318) | 1,320 | 1,654 | ||||||||||||||||
| Net income (loss) attributable to noncontrolling interests | 2 | 2 | 9 | 8 | ||||||||||||||||
| Net income (loss) attributable to Corteva | $ | (570) | $ | (320) | $ | 1,311 | $ | 1,646 | ||||||||||||
| Basic earnings (loss) per share of common stock: | ||||||||||||||||||||
| Basic earnings (loss) per share of common stock from continuing operations | $ | (0.79) | $ | (0.46) | $ | 2.10 | $ | 2.54 | ||||||||||||
| Basic earnings (loss) per share of common stock from discontinued operations | (0.06) | (0.01) | (0.14) | (0.13) | ||||||||||||||||
| Basic earnings (loss) per share of common stock | $ | (0.85) | $ | (0.47) | $ | 1.96 | $ | 2.41 | ||||||||||||
| Diluted earnings (loss) per share of common stock: | ||||||||||||||||||||
| Diluted earnings (loss) per share of common stock from continuing operations | $ | (0.79) | $ | (0.46) | $ | 2.10 | $ | 2.54 | ||||||||||||
| Diluted earnings (loss) per share of common stock from discontinued operations | (0.06) | (0.01) | (0.14) | (0.13) | ||||||||||||||||
| Diluted earnings (loss) per share of common stock | $ | (0.85) | $ | (0.47) | $ | 1.96 | $ | 2.41 |
See Notes to the Interim Consolidated Financial Statements.
Corteva, Inc.
Consolidated Statements of Comprehensive Income (Loss) (Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||
| (In millions) | 2026 | 2025 | 2026 | 2025 | ||||||||||
| Net income (loss) | $ | (568) | $ | (318) | $ | 1,320 | $ | 1,654 | ||||||
| Other comprehensive income (loss) - net of tax: | ||||||||||||||
| Cumulative translation adjustments | (51) | 4 | (173) | 873 | ||||||||||
| Adjustments to pension benefit plans | 1 | (2) | (5) | — | ||||||||||
| Adjustments to other benefit plans | (5) | (3) | (12) | (10) | ||||||||||
| Unrealized gain (loss) on investments | — | — | 1 | 5 | ||||||||||
| Derivative instruments | 40 | (16) | 5 | (60) | ||||||||||
| Total other comprehensive income (loss) | (15) | (17) | (184) | 808 | ||||||||||
| Comprehensive income (loss) | (583) | (335) | 1,136 | 2,462 | ||||||||||
| Comprehensive income (loss) attributable to noncontrolling interests - net of tax | 2 | 2 | 9 | 8 | ||||||||||
| Comprehensive income (loss) attributable to Corteva | $ | (585) | $ | (337) | $ | 1,127 | $ | 2,454 |
See Notes to the Interim Consolidated Financial Statements.
Corteva, Inc.
Consolidated Balance Sheets (Unaudited)
| (In millions, except share and per share amounts) | September 30, 2026 | December 31, 2025 | September 30, 2025 | ||||||||
| Assets | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | 3,932 | $ | 4,521 | $ | 2,509 | |||||
| Marketable securities | 1 | 9 | 77 | ||||||||
| Accounts and notes receivable - net | 7,491 | 6,371 | 7,784 | ||||||||
| Inventories | 5,482 | 5,667 | 5,310 | ||||||||
| Other current assets | 980 | 767 | 758 | ||||||||
| Total current assets | 17,886 | 17,335 | 16,438 | ||||||||
| Investment in nonconsolidated affiliates | 147 | 160 | 141 | ||||||||
| Property, plant and equipment | 9,840 | 9,551 | 9,633 | ||||||||
| Less: Accumulated depreciation | 5,657 | 5,331 | 5,431 | ||||||||
| Net property, plant and equipment | 4,183 | 4,220 | 4,202 | ||||||||
| Goodwill | 10,416 | 10,465 | 10,512 | ||||||||
| Other intangible assets | 7,845 | 8,301 | 8,428 | ||||||||
| Deferred income taxes | 335 | 320 | 434 | ||||||||
| Other assets | 2,219 | 2,044 | 2,043 | ||||||||
| Total Assets | $ | 43,031 | $ | 42,845 | $ | 42,198 | |||||
| Liabilities and Equity | |||||||||||
| Current liabilities | |||||||||||
| Short-term borrowings | $ | 3,988 | $ | 894 | $ | 2,685 | |||||
| Accounts payable | 4,431 | 4,398 | 4,337 | ||||||||
| Income taxes payable | 146 | 155 | 254 | ||||||||
| Deferred revenue | 440 | 3,579 | 483 | ||||||||
| Accrued and other current liabilities | 2,445 | 3,099 | 2,661 | ||||||||
| Total current liabilities | 11,450 | 12,125 | 10,420 | ||||||||
| Long-term debt | 3,458 | 1,686 | 1,688 | ||||||||
| Other noncurrent liabilities | |||||||||||
| Deferred income tax liabilities | 567 | 251 | 373 | ||||||||
| Pension and other post-employment benefits | 877 | 2,434 | 2,215 | ||||||||
| Other noncurrent obligations | 1,942 | 1,963 | 2,041 | ||||||||
| Total noncurrent liabilities | 6,844 | 6,334 | 6,317 | ||||||||
| Commitments and contingen |
Showing the first 8K of 202K characters. Open the full section
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Cautionary Statements About Forward-Looking Statements
This report contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “plans,” “outlook,” “will,” “is designed to,” “is confident that,” “expect,” “expects,” “should,” “could,” “may,” “will continue to,” “believe,” “believes,” “anticipates,” “predicts,” “forecasts,” “estimates,” “projects,” “potential,” “intends,” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; sustainability targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; the anticipated benefits and impacts of Corteva’s separation of its Seed business; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements.
Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond the company’s control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the company’s business, results of operations and financial condition. Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of the company’s products; (ii) failure to successfully develop and commercialize the company’s pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company’s technology and other agricultural products; (iv) failure to comply with competition and antitrust laws; (v) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vi) effect of competition in the company’s industry; (vii) risks related to recent funding and staff reductions at U.S. government agencies; (viii) effect of climate change and unpredictable seasonal and weather factors; (ix) effect of changes in agricultural and related policies of governments and international organizations; (x) risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities; (xi) risk related to geopolitical and military conflict; (xii) effect of volatility in the company’s input costs; (xiii) risks related to the company’s global operations; (xiv) effect of industrial espionage and other disruptions to the company’s supply chain, information technology or network systems; (xv) impact of the company’s dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xvi) failure of the company’s customers to pay their debts to the company, including customer financing programs; (xvii) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xviii) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to the company; (xix) increases in pension and other post-employment benefit plan funding obligations; (xx) risks related to pandemics or epidemics; (xxi) capital markets sentiment towards sustainability matters; (xxii) risk related to the company’s intellectual property rights or defense against intellectual property claims asserted by others; (xxiii) the effect of counterfeit products; (xxiv) risks related to Corteva’s separation from DowDuPont; and (xxv) risks related to Corteva’s separation of its Seed business including, but not limited to, whether the objectives of the separation will be achieved; the terms, structure, benefits and costs of any action or transaction resulting from the separation; risks related to Corteva and Vylor providing services to one another; the risk of any unexpected costs or expenses resulting from the separation and the risk of any litigation as a result of, or relating to, the separation, including but not limited to fraudulent conveyance claims.
Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva’s management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the “Risk Factors” section of Corteva’s Annual Report, as modified by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
Recent Developments
Vylor Separation
On October 1, 2026, the company completed its previously announced separation into two independent, publicly traded companies through the separation of Corteva’s seed operating segment into an independent, publicly traded company, Vylor Inc. The Vylor Separation was effected through a pro rata distribution of all of the outstanding shares of common stock, par value $0.01 per share, of Vylor to holders of common stock, par value $0.01 per share, of Corteva as of the close of business on September 24, 2026. The transaction was intended to be a tax-free spin-off for U.S. federal income tax purposes.
2026 Restructuring Actions
On March 15, 2026, management of the company approved a restructuring program designed to align the company’s organizational structure and geographic footprint with the operational needs of each function as the company prepared for the intended separation of its businesses (the “2026 Restructuring Actions”). The restructuring actions primarily consist of workforce reductions across commercial and functional support areas and are intended to right‑size the organization and support the future standalone operating models. The restructuring actions are expected to be substantially complete by December 2026.
The company expects to incur aggregate pre‑tax restructuring and asset related charges of approximately $70 million to $80 million in connection with the 2026 Restructuring Actions, consisting solely of severance and related benefit costs. Reductions in workforce are subject to local regulatory requirements. For the nine months ended September 30, 2026, the
Showing the first 8K of 89K characters. Open the full section
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
See Note 15 - Financial Instruments, to the interim Consolidated Financial Statements. See also Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of the company’s 2025 Annual Report, for information on the company’s utilization of financial instruments and an analysis of the sensitivity of these instruments.
Item 4. CONTROLS AND PROCEDURES
Corteva, Inc.
a) Evaluation of Disclosure Controls and Procedures
The company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the company’s reports filed or submitted under the Securities Exchange Act of 1934 (“Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.
As of September 30, 2026, the company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), together with management, conducted an evaluation of the effectiveness of the company’s disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.
b) Changes in Internal Control over Financial Reporting
There have been no changes in the company’s internal control over financial reporting that occurred during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, the company’s internal control over financial reporting.
EIDP, Inc.
a) Evaluation of Disclosure Controls and Procedures
EIDP maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in EIDP’s reports filed or submitted under the Securities Exchange Act of 1934 (“Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.
As of September 30, 2026, EIDP’s CEO and CFO, together with management, conducted an evaluation of the effectiveness of EIDP’s disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.
b) Changes in Internal Control over Financial Reporting
There have been no changes in EIDP’s internal control over financial reporting that occurred during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, EIDP’s internal control over financial reporting.
PART II. OTHER INFORMATION
**Item 1.**LEGAL PROCEEDINGS
The company is subject to various legal proceedings, including, but not limited to, product liability, intellectual property, antitrust, commercial, property damage, personal injury, environmental and regulatory matters arising out of the normal course of its current businesses or legacy EIDP businesses unrelated to Corteva’s current businesses but allocated to Corteva as part of the Corteva Separation from DuPont.
Often these proceedings raise complex factual and legal issues, which are subject to risks and uncertainties and which could require significant amounts of the senior leadership team’s time. Litigation and other claims, along with regulatory proceedings, against the company could also materially adversely affect its operations, reputation, and/or result in the incurrence of unexpected expenses and liability. Even when the company believes liabilities are not expected to be material or the probability of loss or of an adverse unappealable final judgment is remote, the company may consider settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the company, including avoidance of future distraction and litigation defense cost, and its shareholders. Information regarding certain of these matters is set forth below and in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.
Litigation related to Corteva’s current businesses
Further information with respect to litigation matters related to Corteva’s current business is set forth under “Federal Trade Commission Investigation” and “Chlorpyrifos Lawsuits” in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.
Litigation related to legacy Vylor business
Inari Disputes
On September 27, 2023, Corteva filed a lawsuit in Delaware federal court against Inari Agriculture, Inc. and Inari Agriculture N.V. (collectively “Inari”) asserting claims of Plant Variety Protection infringement, indirect patent infringement, breach of contract, and civil conversion. Corteva’s lawsuit alleges Inari illegally obtained various varieties of seed technologies from a seed depository and illegally transported them abroad for the purpose of performing gene editing on the technologies and then filing a patent for such technologies. In August 2024, the court denied Inari’s motion to dismiss the complaint. In September 2024, Corteva amended its complaint to include additional infringement claims with respect to soybean and corn technologies. In May 2025, the federal court dismissed Inari’s claims of sham litigation, patent misuse, and state-based deceptive trade practices claims. This May 2025 order was amended to reinstate Inari’s estoppel defense. After a three-day trial commenced on September 23, 2026, the parties entered into a confidential settlement where Inari agreed to destroy Corteva material it accessed from seed depositories and material developed from the deposits and assign to Corteva the intellectual property related to its edited versions of Corteva events.
Bayer Disputes
Corteva resolved its outstanding litigation with Bayer. Further information with respect to these proceedings and their respective resolution is set forth under “Bayer Disputes” in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.
Litigation related to legacy EIDP businesses unrelated to Corteva’s current businesses
As discussed below and in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, certain of the environmental proceedings and litigation allocated to Corteva as part of the Corteva Separation from DuPont relate to the legacy EIDP businesses, including their use of PFOA, which, for purposes of this report, means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms, and PFAS, which means per- and polyfluoroalkyl substances, including PFOA, PFOS (perfluorooctanesulfonic acid), GenX and other perfluorinated chemicals and compounds (“PFCs”). This litigation includes multiple natural resource damage lawsuits across the United States filed by municipalities and alleging PFOA contamination, as well as, lawsuits by four municipalities in the Netherlands alleging contamination of land and groundwater resulting from the emission of PFOA and GenX by Corteva, DuPont and Chemours.
In addition to the matters set forth in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, on March 25, 2019, the New Jersey Department of Environmental Protection (“NJDEP”) issued a Statewide PFAS Directive to several companies, including Chemours, DuPont, and EIDP. The Directive seeks information relating to the use and environmental release of PFAS and PFAS-replacement chemicals at and from two former EIDP sites in New Jersey, Chambers Works and Parlin, and a funding source for costs related to the NJDEP’s investigation of PFAS issues and PFAS
testing and remediation. This matter was resolved upon the court’s approval of the NJ Statewide Settlement described in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.
Other Environmental Proceedings
The company believes it is remote that the following matters will have a material impact on its financial position, liquidity or results of operations. The matters below involve the potential for $1 million or more in monetary fines and are included per Item 103(3)(c)(iii) of Regulation S-K of the Securities Exchange Act of 1934, as amended.
Related to legacy Vylor business
Nebraska Department of Environment and Energy, AltEn Facility
The EPA and the Nebraska Department of Environment and Energy (“NDEE”) are pursuing investigations, response and removal actions, litigation and enforcement action related to an ethanol plant located near Mead, Nebraska and owned and operated by AltEn LLC (“AltEn”). Corteva is one of six seed companies, who were customers of AltEn (collectively, the “Facility Response Group”), participating in the NDEE’s Voluntary Cleanup Program to address certain interim remediation needs at the site. Further information with respect to these proceedings is set forth under “Nebraska Department of Environment and Energy, AltEn Facility” in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.
AZ Concordia Chile Site
On February 9, 2026, a water reservoir at the AZ Concordia site overflowed during a refilling, resulting in the collapse of part of the embankment and the release of all stored water beyond Corteva’s facilities resulting in flooding and other damage impacting government-managed infrastructure and wastewater systems. Corteva is working with local authorities on the resolution of matters related to this incident.
Related to legacy EIDP businesses unrelated to Corteva’s current businesses
Divested Neoprene Facility, La Place, Louisiana - EPA Compliance Inspection
In 2016, the EPA conducted a focused compliance investigation at the Denka Performance Elastomer LLC (“Denka”) neoprene manufacturing facility in La Place, Louisiana. EIDP sold the neoprene business, including this manufacturing facility, to Denka in the fourth quarter of 2015. In the spring of 2017, the EPA, the DOJ, the Louisiana Department of Environmental Quality, EIDP and Denka began discussions relating to the inspection conclusions and allegations of noncompliance arising under the Clean Air Act, including leak detection and repair. In March 2025, the EPA and DOJ dismissed the action against Denka and EIDP. Following the dismissal, a private action mirroring the government’s original claims was filed, as well as adding allegations of violations of the U.S. Resource Conservation and Recovery Act and U.S. Clean Water Act. Under the Corteva Separation Agreement, DuPont is defending and indemnifying the company in this matter.
New Jersey Directive Pompton Lakes
On March 27, 2019, the NJDEP issued to Chemours and EIDP a Natural Resource Damages Directive relating to chemical contamination (non-PFAS) at and around EIDP’s former Pompton Lakes facility in New Jersey. The Directive alleges that this contamination has harmed the natural resources of New Jersey. It seeks $125,000 as reimbursement for the cost of preparing a natural resource damages assessment, which the State will use to determine the extent of such damage and the amount it expects to seek to restore the affected natural resources to their pre-damage state. This matter was resolved upon the court’s approval of the NJ Statewide Settlement described in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.
EPA CERCLA Claim
In April 2024, the U.S. Environmental Protection Agency (“EPA”) also designated PFOA and PFAS as hazardous substances under the Comprehensive Environmental Response, Compensation, and Liability Act (“CERCLA”). In November 2024, the EPA issued a letter to DuPont, EIDP and Corteva asserting CERCLA claims related to alleged PFAS contamination from six historical and present DuPont and Chemours sites and providing a demand for cleanup and restoration costs. In September 2025, the EPA announced its intent to retain the designation of PFOA and PFOS as CERCLA hazardous substances. Discussions among the parties are ongoing.
Item 1A. RISK FACTORS
Risks Related to Our Industry
Corteva may not be able to obtain or maintain the necessary regulatory approvals for some of its products, which could restrict its ability to sell those products in some markets.
Regulatory and legislative requirements affect the development, manufacture and distribution of Corteva’s products, and non-compliance with these requirements can harm Corteva’s sales and profitability.
Our products must be extensively tested for safety, efficacy and environmental impact before they can be registered for production, use, sale or commercialization in a given market. In certain jurisdictions, Corteva must periodically renew its approvals for its crop protection products, which typically require Corteva to demonstrate compliance with then-current standards which generally are more stringent since the prior registration. The regulatory approvals process is lengthy, costly, complex and in some markets unpredictable, with requirements that can vary by product, technology, industry and country. The regulatory approvals process for products that incorporate novel modes of action or new technologies can be particularly unpredictable and uncertain due to the then-current state of regulatory guidelines and objectives, as well as governmental policy considerations and non-governmental organization and other stakeholder considerations. The uncertainty and increased length of regulatory approvals may reduce Corteva’s return on its research and development investments, and impede its ability to meet its sales, profitability, or sustainability expectations.
Furthermore, the detection of chemical residues from a crop protection product not approved in the country in which Corteva sells its product, or in a country to which Corteva imports its product, may affect Corteva’s ability to supply or export its products, or even result in crop destruction, product recalls trade disruptions, or disputes with customers and distributors.
Additionally, the regulatory environment may be impacted by the activities of non-governmental organizations and special interest groups and stakeholder reaction to actual or perceived impacts of new and existing technology, products or processes on safety, health and the environment. Obtaining and maintaining regulatory approvals requires submitting a significant amount of information and data, which may require participation from technology providers. Regulatory standards and trial procedures are continuously changing. In addition, Corteva has seen an increase in recent years in the number of lawsuits filed by those who identify themselves as public or environmental interest groups seeking to invalidate pesticide product registrations, including those for Enlist One®, and/or challenge the way federal or state governmental entities apply the rules and regulations governing pesticide produce use. The pace of change together with the lack of regulatory harmony could result in unintended noncompliance. Responding to these changes and meeting existing and new requirements may involve significant costs or capital expenditures or require changes in business practice that could result in reduced profitability. The failure to receive necessary permits or approvals, or the invalidation thereof, could have near- and long-term effects on Corteva’s ability to produce and sell some current and future products.
The successful development and commercialization of Corteva’s pipeline products will be necessary for Corteva’s growth.
Corteva conducts research into biological and chemical products to protect farmers’ crops from pests and diseases and enhance plant productivity. However, new product concepts may be abandoned for many reasons, including greater anticipated development costs, technical difficulties, lack of efficacy, regulatory obstacles or inability to market under regulatory frameworks, competition, inability to prove the original concept, lack of demand and the need to divert focus, from time to time, to other initiatives with perceived opportunities for better returns. The processes of active ingredient development or discovery is lengthy, and a very small percentage of the chemicals or biologicals Corteva tests are selected for commercialization. Commercial transitions to the company’s new technologies can take several years to complete, and weed and insect resistance may develop faster than Corteva can respond with new technologies or enhancements to existing technologies. Even when initial commercialization efforts have been promising, there are no guarantees that anticipated levels of product acceptability within Corteva’s markets will be achieved or that higher quality products will not be developed by Corteva’s competitors in the future.
Speed in discovering, developing, protecting and responding to new technologies, including artificial intelligence and new technology-based distribution channels that accelerate Corteva’s product development timelines and could facilitate its ability to engage with customers and end users, and bringing related products to market is a significant competitive advantage. Commercial success frequently depends on being the first company to the market, and many of Corteva’s competitors are also making considerable investments in similar biological and chemical products.
The degree of public understanding and acceptance or perceived public acceptance of Corteva’s products and technologies can affect Corteva’s sales and results of operations by affecting labelling approvals, regulatory requirements and customer purchase decisions.
Concerns and claims regarding the safe use of crop protection products and their potential impact on health and the environment reflect a growing trend in societal demands for increasing levels of product safety and environmental protection. These include concerns and claims that increased use of crop protection products, drift, inversion, volatilization and the use of biotechnology traits meant to reduce the resistance of weeds or pests to control by crop protection products, could increase or accelerate such resistance and otherwise negatively impact health and the environment. These and other concerns could manifest themselves in delays or failures in obtaining or retaining regulatory approvals, delayed product launches, lack of market acceptance, product discontinuation, litigation, continued pressure for and adoption of more stringent regulatory intervention, termination of raw material supply agreements, legal claims, preferred purchases and stockholder proposals. These and other concerns could also influence public perceptions, the viability or continued sales of certain of Corteva’s products, Corteva’s reputation and the cost to comply with regulations. As a result, such concerns could have a material adverse effect on Corteva’s business, results of operations, financial condition and cash flows.
Corteva’s business is subject to various competition and antitrust, rules and regulations around the world, and as the size of its business grows, scrutiny of its business by legislators and regulators in these areas may intensify.
In 2026, Corteva, without admitting any wrongdoing, entered into settlement agreements with the FTC and the attorney generals of several states related to allegations of anti-competitive conduct resulting from its customer loyalty programs. Scrutiny from regulators in the U.S. and abroad may intensify as Corteva’s business presence grows, industry concentration increases, or as social political concerns related to the cost of food and farming inputs rises.. This scrutiny and related investigations, even absent enforcement action or other litigation, may result in damage to a company’s reputation, significant defense expense, as well as become a distraction to management. Antitrust and competition enforcement actions against Corteva has resulted in regulators imposing fines, penalties, or restrictions on
Showing the first 8K of 70K characters. Open the full section
Item 5. OTHER INFORMATION
None.
Item 6. EXHIBITS
| Exhibit Number | Description | |||||||
| 2.1 | Separation and Distribution Agreement by and among DowDuPont Inc., Dow Inc. and Corteva, Inc. (incorporated by reference to Exhibit No. 2.1 to Amendment 3 to Corteva’s Registration Statement on Form 10 (Commission file number 001-38710), filed on April 16, 2019). | |||||||
| 2.2 | Separation and Distribution Agreement by and among Corteva, Inc., Vylor Inc., and solely for the purposes set forth therein, EIDP, Inc. (incorporated by reference to Exhibit 2.1 to Corteva’s and EIDP’s Current Report on Form 8-K (Commission file numbers 001-38710 and 001-00815) filed on October 5, 2026). | |||||||
| 3.1 | Amended and Restated Certificate of Incorporation of Corteva, Inc. (incorporated by reference to Exhibit No. 3.1 to Corteva’s Current Report on Form 8-K (Commission file number 001-38710), filed on May 2, 2024). | |||||||
| 3.2 | Amended and Restated Bylaws of Corteva, Inc. (incorporated by reference to Exhibit No. 3.1 to Corteva’s Current Report on Form 8-K (Commission file number 001-38710), filed on December 21, 2022). | |||||||
| 3.3 | Amended and Restated Certificate of Incorporation of EIDP, Inc. (incorporated by reference to Exhibit No. 3.3 to Corteva’s and EIDP’s Quarterly Report on Form 10-Q (Commission file numbers 001-38710 and 001-00815), filed on May 4, 2023). | |||||||
| 3.4 | Amended and Restated Bylaws of EIDP, Inc. (incorporated by reference to Exhibit 3.2 to EIDP’s Current Report on Form 8-K (Commission file number 001-00815) dated September 1, 2017). | |||||||
| 4.1 | Indenture dated as of May 15, 2020, between EIDP, Inc. and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit No. 4.1 to Corteva, Inc.’s Current Report on Form 8-K (Commission file number 001-38710), filed on May 15, 2020). | |||||||
| 4.2 | First Supplemental Indenture, dated as of May 15, 2020, between E.I. du Pont de Nemours and Company and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit No. 4.2 to Corteva’s Current Report on Form 8-K (Commission file number 001-38710), filed on May 13, 2020). | |||||||
| 4.3 | Second Supplemental Indenture, dated as of May 15, 2023, between EIDP, Inc. and U.S. Bank Trust Company, National Association, as trustee (incorporated by reference to Exhibit No. 4.1 to Corteva’s Current Report on Form 8-K (Commission file number 001-38710), filed on May 15, 2023). | |||||||
| 4.4 | Third Supplemental Indenture, dated as of May 14, 2025, between EIDP, Inc. and U.S. Bank Trust Company, National Association, as trustee. (incorporated by reference to Exhibit No. 4.1 to EIDP’s Current Report on Form 8-K (Commission file number 001-00815) filed on May 14, 2025). | |||||||
| 4.5 | Fourth Supplemental Indenture, dated as of August 20, 2026, between EIDP, Inc. and U.S. Bank Trust Company, National Association, as trustee (incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K of Corteva, Inc. and EIDP, Inc. (Commission file number 001-38710), filed August 20, 2026). | |||||||
| 4.6 | Fifth Supplemental Indenture, dated as of September 24, 2026, between EIDP, Inc. and U.S. Bank Trust Company, National Association, as trustee (i(incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K of Corteva, Inc. and EIDP, Inc. (Commission file number 001-38710), filed September 24, 2026). | |||||||
| 10.1 | Tax Matters Agreement by and among Corteva, Inc., Vylor Inc. and EIDP, Inc. (incorporated by reference to Exhibit 10.1 to Corteva’s and EIDP’s Current Report on Form 8-K (Commission file numbers 001-38710 and 001-00815) filed on October 5, 2026). | |||||||
| 10.2 | Employee Matters Agreement by and between Corteva, Inc. and Vylor Inc. (incorporated by reference to Exhibit 10.2 to Corteva’s and EIDP’s Current Report on Form 8-K (Commission file numbers 001-38710 and 001-00815) filed on October 5, 2026). | |||||||
| 10.3 | Transition Services Agreement by and between Corteva, Inc. and Vylor Inc. (incorporated by reference to Exhibit 10.3 to Corteva’s and EIDP’s Current Report on Form 8-K (Commission file numbers 001-38710 and 001-00815) filed on October 5, 2026). | |||||||
| 10.4 | Intellectual Property Matters Agreement by and between Corteva, Inc. and Vylor Inc. (incorporated by reference to Exhibit 10.4 to Corteva’s and EIDP’s Current Report on Form 8-K (Commission file numbers 001-38710 and 001-00815) filed on October 5, 2026). | |||||||
| 10.5 | Global Master Seed Treatment Supply Agreement by and between Corteva, Inc. and Vylor Inc. (incorporated by reference to Exhibit 10.5 to Corteva’s and EIDP’s Current Report on Form 8-K (Commission file numbers 001-38710 and 001-00815) filed on October 5, 2026). | |||||||
| 21.1 | List of Subsidiaries | |||||||
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification of the company’s and EIDP’s Principal Executive Officer. | |||||||
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification of the company’s and EIDP’s Principal Financial Officer. | |||||||
| 32.1 | Section 1350 Certification of the company’s and EIDP’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended. | |||||||
| 32.2 | Section 1350 Certification of the company’s and EIDP’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended. | |||||||
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||||
| 104 | Cover Page Interactive Data File – The Cover Page XBRL tags are embedded within the Inline XBRL document (included in Exhibit 101.INS) |
SIGNATURE
Corteva, Inc.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Corteva, Inc. | ||||||||
| (Registrant) | ||||||||
| Date: | November 12, 2026 | |||||||
| By: | /s/ Brian J. Titus | |||||||
| Brian J. Titus | ||||||||
| Vice President, Corporate Finance and Accounting Officer | ||||||||
| (Principal Accounting Officer) |
EIDP, Inc.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| EIDP, Inc. | ||||||||
| (Registrant) | ||||||||
| Date: | November 12, 2026 | |||||||
| By: | /s/ Brian J. Titus | |||||||
| Brian J. Titus | ||||||||
| Vice President, Corporate Finance and Accounting Officer | ||||||||
| (Principal Accounting Officer) |
EIDP, Inc.
Index to the Consolidated Financial Statements
CONSOLIDATED FINANCIAL STATEMENTS OF EIDP, Inc.
EIDP, Inc.
Consolidated Statements of Operations (Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||
| (In millions, except per share amounts) | 2026 | 2025 | 2026 | 2025 | ||||||||||
| Net sales | $ | 2,458 | $ | 2,618 | $ | 13,742 | $ | 13,491 | ||||||
| Cost of goods sold | 1,534 | 1,644 | 6,624 | 6,918 | ||||||||||
| Research and development expense | 397 | 351 | 1,126 | 1,061 | ||||||||||
| Selling, general and administrative expenses | 732 | 725 | 2,773 | 2,632 | ||||||||||
| Amortization of intangibles | 159 | 162 | 513 | 485 | ||||||||||
| Restructuring and asset related charges - net | 17 | 30 | 158 | 131 | ||||||||||
| Separation costs | 99 | 7 | 230 | 7 | ||||||||||
| Other income (expense) - net | (34) | (23) | (266) | 95 | ||||||||||
| Interest expense | 75 | 46 | 158 | 134 | ||||||||||
| Income (loss) from continuing operations before income taxes | (589) | (370) | 1,894 | 2,218 | ||||||||||
| Provision for (benefit from) income taxes on continuing operations | (62) | (62) | 479 | 477 | ||||||||||
| Income (loss) from continuing operations after income taxes | (527) | (308) | 1,415 | 1,741 | ||||||||||
| Income (loss) from discontinued operations after income taxes | (41) | (10) | (95) | (87) | ||||||||||
| Net income (loss) | (568) | (318) | 1,320 | 1,654 | ||||||||||
| Net income (loss) attributable to noncontrolling interests | — | — | 2 | 1 | ||||||||||
| Net income (loss) attributable to EIDP, Inc. | $ | (568) | $ | (318) | $ | 1,318 | $ | 1,653 |
See Notes to the EIDP Interim Consolidated Financial Statements.
EIDP, Inc.
Consolidated Statements of Comprehensive Income (Loss) (Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||
| (In millions) | 2026 | 2025 | 2026 | 2025 | ||||||||||
| Net income (loss) | $ | (568) | $ | (318) | $ | 1,320 | $ | 1,654 | ||||||
| Other comprehensive income (loss) - net of tax: | ||||||||||||||
| Cumulative translation adjustments | (51) | 4 | (173) | 873 | ||||||||||
| Adjustments to pension benefit plans | 1 | (2) | (5) | — | ||||||||||
| Adjustments to other benefit plans | (5) | (3) | (12) | (10) | ||||||||||
| Unrealized gain (loss) on investments | — | — | 1 | 5 | ||||||||||
| Derivative instruments | 40 | (16) | 5 | (60) | ||||||||||
| Total other comprehensive income (loss) | (15) | (17) | (184) | 808 | ||||||||||
| Comprehensive income (loss) | (583) | (335) | 1,136 | 2,462 | ||||||||||
| Comprehensive income (loss) attributable to noncontrolling interests - net of tax | — | — | 2 | 1 | ||||||||||
| Comprehensive income (loss) attributable to EIDP, Inc. | $ | (583) | $ | (335) | $ | 1,134 | $ | 2,461 |
See Notes to the EIDP Interim Consolidated Financial Statements.
EIDP, Inc.
Consolidated Balance Sheets (Unaudited)
| (In millions, except share amounts) | September 30, 2026 | December 31, 2025 | September 30, 2025 | ||||||||
| Assets | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | 3,932 | $ | 4,521 | $ | 2,509 | |||||
| Marketable securities | 1 | 9 | 77 | ||||||||
| Accounts and notes receivable - net | 7,491 | 6,371 | 7,784 | ||||||||
| Inventories | 5,482 | 5,667 | 5,310 | ||||||||
| Other current assets | 980 | 767 | 758 | ||||||||
| Total current assets | 17,886 | 17,335 | 16,438 | ||||||||
| Investment in nonconsolidated affiliates | 147 | 160 | 141 | ||||||||
| Property, plant and equipment | 9,840 | 9,551 | 9,633 | ||||||||
| Less: Accumulated depreciation | 5,657 | 5,331 | 5,431 | ||||||||
| Net property, plant and equipment | 4,183 | 4,220 | 4,202 | ||||||||
| Goodwill | 10,416 | 10,465 | 10,512 | ||||||||
| Other intangible assets | 7,845 | 8,301 | 8,428 | ||||||||
| Deferred income taxes | 335 | 320 | 434 | ||||||||
| Other assets | 2,219 | 2,044 | 2,043 | ||||||||
| Total Assets | $ | 43,031 | $ | 42,845 | $ | 42,198 | |||||
| Liabilities and Equity | |||||||||||
| Current liabilities | |||||||||||
| Short-term borrowings | $ | 3,988 | $ | 894 | $ | 2,685 | |||||
| Accounts payable | 4,431 | 4,398 | 4,337 | ||||||||
| Income taxes payable | 146 | 155 | 254 | ||||||||
| Deferred revenue | 440 | 3,579 | 483 | ||||||||
| Accrued and other current liabilities | 2,449 | 3,223 | 3,014 | ||||||||
| Total current liabilities | 11,454 | 12,249 | 10,773 | ||||||||
| Long-term debt | 3,458 | 1,686 | 1,688 | ||||||||
| Other noncurrent liabilities | |||||||||||
| Deferred income tax liabilities | 567 | 251 | 373 | ||||||||
| Pension and other post-employment benefits | 877 | 2,434 | 2,215 | ||||||||
| Other noncurrent obligations | 1,942 | 1,963 | 2,041 | ||||||||
| Total noncurrent liabilities | 6,844 | 6,334 | 6,317 | ||||||||
| Commitments and contingent liabilities | |||||||||||
| Stockholders’ equity | |||||||||||
| Preferred stock, without par value – cumulative; 23,000,000 shares authorized; issued at September 30, 2026, December 31, 2025, and September 30, 2025: | |||||||||||
| $4.50 Series – 1,673,000 shares (callable at $120) | 169 | 169 | 169 | ||||||||
| $3.50 Series – 700,000 shares (callable at $102) | 70 | 70 | 70 | ||||||||
| Common stock, $0.30 par value; 1,800,000,000 shares authorized; 200 issued at September 30, 2026, December 31, 2025, and September 30, 2025 | — | — | — | ||||||||
| Additional paid-in capital | 24,699 | 24,610 | 24,574 | ||||||||
| Retained earnings (accumulated deficit) | 2,771 | 2,207 | 2,953 | ||||||||
| Accumulated other comprehensive income (loss) | (2,981) | (2,797) | (2,661) | ||||||||
| Total EIDP, Inc. stockholders’ equity | 24,728 | 24,259 | 25,105 | ||||||||
| Noncontrolling interests | 5 | 3 | 3 | ||||||||
| Total equity | 24,733 | 24,262 | 25,108 | ||||||||
| Total Liabilities and Equity | $ | 43,031 | $ | 42,845 | $ | 42,198 |
See Notes to the EIDP Interim Consolidated Financial Statements.
EIDP, Inc.
Consolidated Statements of Cash Flows (Unaudited)
| Nine Months Ended September 30, | ||||||||
| (In millions) | 2026 | 2025 | ||||||
| Operating activities | ||||||||
| Net income (loss) | $ | 1,320 | $ | 1,654 | ||||
| (Income) loss from discontinued operations after income taxes | 95 | 87 | ||||||
| Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities: | ||||||||
| Depreciation and amortization | 942 | 897 | ||||||
| Provision for (benefit from) deferred income tax | 280 | (72) | ||||||
| Net periodic pension and OPEB (benefit) cost, net | (7) | 27 | ||||||
| Pension and OPEB contributions | (1,567) | (110) | ||||||
| Net (gain) loss on sales of property, businesses, consolidated companies, and investments | 3 | (17) | ||||||
| Restructuring and asset related charges - net | 158 | 131 | ||||||
| Other net loss | 441 | 386 | ||||||
| Changes in assets and liabilities, net | ||||||||
| Accounts and notes receivable | (1,372) | (1,659) | ||||||
| Inventories | 163 | 331 | ||||||
| Accounts payable | (47) | 123 | ||||||
| Deferred revenue | (3,130) | (2,824) | ||||||
| Other assets and liabilities | (1,157) | 105 | ||||||
| Cash provided by (used for) operating activities - continuing operations | (3,878) | (941) | ||||||
| Cash provided by (used for) operating activities - discontinued operations | (70) | (28) | ||||||
| Cash provided by (used for) operating activities | (3,948) | (969) | ||||||
| Investing activities | ||||||||
| Capital expenditures | (354) | (369) | ||||||
| Proceeds from sales of property, businesses, and consolidated companies - net of cash divested | 10 | 26 | ||||||
| Acquisitions of businesses - net of cash acquired | (43) | — | ||||||
| Investments in and loans to nonconsolidated affiliates | (7) | (7) | ||||||
| Proceeds from sales and maturities of investments | 8 | 68 | ||||||
| Proceeds from (payments for) settlement of net investment hedge | — | (56) | ||||||
| Other investing activities, net | (4) | (17) | ||||||
| Cash provided by (used for) investing activities | (390) | (355) | ||||||
| Financing activities | ||||||||
| Net change in borrowings (less than 90 days) | 3,264 | 1,119 | ||||||
| Net payments from (advances to) Parent on in-house banking arrangement | — | 129 | ||||||
| Proceeds from debt | 2,660 | 1,643 | ||||||
| Payments on debt | (1,059) | (1,116) | ||||||
| Proceeds from exercise of stock options | 38 | 75 | ||||||
| Dividends paid to Parent | (870) | (1,260) | ||||||
| Other financing activities, net | (44) | (36) | ||||||
| Cash provided by (used for) financing activities | 3,989 | 554 | ||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | (27) | 85 | ||||||
| Increase (decrease) in cash, cash equivalents and restricted cash equivalents | (376) | (685) | ||||||
| Cash, cash equivalents and restricted cash equivalents at beginning of period | 4,725 | 3,422 | ||||||
| Cash, cash equivalents and restricted cash equivalents at end of period | $ | 4,349 | $ | 2,737 |
See Notes to the EIDP Interim Consolidated Financial Statements.
EIDP, Inc.
Consolidated Statements of Equity (Unaudited)
| (In millions) | Preferred Stock | Common Stock | Additional Paid-in Capital | Due from Parent | Retained Earnings (Accum. Deficit) | Accum. Other Comp. Income (Loss) | Non-Controlling Interests | Total Equity | ||||||||||||||||||
| 2026 | ||||||||||||||||||||||||||
| Balance at January 1, 2026 | $ | 239 | $ | — | $ | 24,610 | $ | — | $ | 2,207 | $ | (2,797) | $ | 3 | $ | 24,262 | ||||||||||
| Net income (loss) | 722 | 1 | 723 | |||||||||||||||||||||||
| Other comprehensive income (loss) | (143) | (143) | ||||||||||||||||||||||||
| Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share) | (2) | (2) | ||||||||||||||||||||||||
| Issuance of Corteva stock | 17 | 17 | ||||||||||||||||||||||||
| Share-based compensation | (2) | (2) | ||||||||||||||||||||||||
| Dividend to Parent | (627) | (627) | ||||||||||||||||||||||||
| Other - net | (1) | (1) | ||||||||||||||||||||||||
| Balance at March 31, 2026 | $ | 239 | $ | — | $ | 24,624 | $ | — | $ | 2,300 | $ | (2,940) | $ | 4 | $ | 24,227 | ||||||||||
| Net income (loss) | 1,164 | 1 | 1,165 | |||||||||||||||||||||||
| Other comprehensive income (loss) | (26) | (26) | ||||||||||||||||||||||||
| Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share) | (3) | (3) | ||||||||||||||||||||||||
| Issuance of Corteva stock | 14 | 14 | ||||||||||||||||||||||||
| Share-based compensation | 21 | (1) | 20 | |||||||||||||||||||||||
| Other - net | — | |||||||||||||||||||||||||
| Balance at June 30, 2026 | $ | 239 | $ | — | $ | 24,659 | $ | — | $ | 3,460 | $ | (2,966) | $ | 5 | $ | 25,397 | ||||||||||
| Net income (loss) | (568) | (568) | ||||||||||||||||||||||||
| Other comprehensive income (loss) | (15) | (15) | ||||||||||||||||||||||||
| Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share) | (3) | (3) | ||||||||||||||||||||||||
| Issuance of Corteva Stock | 7 | 7 | ||||||||||||||||||||||||
| Share-based compensation | 33 | (1) | 32 | |||||||||||||||||||||||
| Dividend to Parent | (118) | (118) | ||||||||||||||||||||||||
| Other - net | 1 | 1 | ||||||||||||||||||||||||
| Balance at September 30, 2026 | $ | 239 | $ | — | $ | 24,699 | $ | — | $ | 2,771 | $ | (2,981) | $ | 5 | $ | 24,733 |
| (In millions) | Preferred Stock | Common Stock | Additional Paid-in Capital | Due from Parent | Retained Earnings (Accum. Deficit) | Accum. Other Comp. Income (Loss) | Non-Controlling Interests | Total Equity | ||||||||||||||||||
| 2025 | ||||||||||||||||||||||||||
| Balance at January 1, 2025 | $ | 239 | $ | — | $ | 24,464 | $ | (129) | $ | 2,930 | $ | (3,469) | $ | 2 | $ | 24,037 | ||||||||||
| Net income (loss) | 655 | 1 | 656 | |||||||||||||||||||||||
| Other comprehensive income (loss) | 198 | 198 | ||||||||||||||||||||||||
| Due from Parent | 129 | 129 | ||||||||||||||||||||||||
| Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share) | (3) | (3) | ||||||||||||||||||||||||
| Issuance of Corteva stock | 35 | 35 | ||||||||||||||||||||||||
| Share-based compensation | (2) | (2) | ||||||||||||||||||||||||
| Dividend to Parent | (513) | (513) | ||||||||||||||||||||||||
| Other - net | 1 | 1 | ||||||||||||||||||||||||
| Balance at March 31, 2025 | $ | 239 | $ | — | $ | 24,497 | $ | — | $ | 3,070 | $ | (3,271) | $ | 3 | $ | 24,538 | ||||||||||
| Net income (loss) | 1,316 | 1,316 | ||||||||||||||||||||||||
| Other comprehensive income (loss) | 627 | 627 | ||||||||||||||||||||||||
| Due from Parent | — | |||||||||||||||||||||||||
| Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share) | (2) | (2) | ||||||||||||||||||||||||
| Issuance of Corteva stock | 35 | 35 | ||||||||||||||||||||||||
| Share-based compensation | 17 | 17 | ||||||||||||||||||||||||
| Dividend to Parent | (375) | (375) | ||||||||||||||||||||||||
| Other - net | (1) | (1) | ||||||||||||||||||||||||
| Balance at June 30, 2025 | $ | 239 | $ | — | $ | 24,548 | $ | — | $ | 4,009 | $ | (2,644) | $ | 3 | $ | 26,155 | ||||||||||
| Net income (loss) | (318) | (318) | ||||||||||||||||||||||||
| Other comprehensive income (loss) | (17) | (17) | ||||||||||||||||||||||||
| Due from Parent | — | |||||||||||||||||||||||||
| Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share) | (2) | (2) | ||||||||||||||||||||||||
| Issuance of Corteva stock | 5 | 5 | ||||||||||||||||||||||||
| Share-based compensation | 19 | (1) | 18 | |||||||||||||||||||||||
| Dividend to Parent | (732) | (732) | ||||||||||||||||||||||||
| Other - net | 2 | (3) | (1) | |||||||||||||||||||||||
| Balance at September 30, 2025 | $ | 239 | $ | — | $ | 24,574 | $ | — | $ | 2,953 | $ | (2,661) | $ | 3 | $ | 25,108 |
See Notes to the EIDP Interim Consolidated Financial Statements.
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
| EIDP, Inc. | ||||||||
| Notes to the Interim Consolidated Financial Statements (Unaudited) |
Table of Contents
| Note | Page | |||||||
| 1 | Basis of Presentation | 93 | ||||||
| 2 | Related Party Transactions | 93 | ||||||
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION
Corteva, Inc. owns 100 percent of the outstanding common stock of EIDP. EIDP is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. The primary differences between Corteva, Inc. and EIDP are outlined below:
-
Preferred Stock - EIDP has preferred stock outstanding to third parties which is accounted for as a non-controlling interest at the Corteva, Inc. level. Each share of EIDP Preferred Stock - $4.50 Series and EIDP Preferred Stock - $3.50 Series issued and outstanding at the effective date of the Corteva Distribution remains issued and outstanding as to EIDP and was unaffected by the Corteva Distribution.
-
Physical Cash Pooling Arrangement - A physical cash pooling arrangement exists to which EIDP is a party, along with Corteva and certain consolidated subsidiaries, as more fully described in EIDP Note 2 - Related Party Transactions, to the EIDP interim Consolidated Financial Statements.
-
Dividends -** The Board of Directors of EIDP authorizes and declares a quarterly dividend to Corteva, Inc., from which the proceeds are intended to be used to fund Corteva, Inc. share repurchases and common stock dividends generally during the subsequent quarter.
-
Capital Structure - At September 30, 2026, Corteva, Inc.’s capital structure consists of 667,304,000 issued shares of common stock, par value $0.01 per share.
The accompanying footnotes relate to EIDP only, and not to Corteva, Inc., and are presented to show differences between EIDP and Corteva, Inc.
For the footnotes listed below, refer to the following footnotes of the Corteva interim Consolidated Financial Statements:
-
Note 1 - Summary of Significant Accounting Policies
-
Note 2 - Recent Accounting Guidance
-
Note 3 - Revenue
-
Note 4 - Restructuring and Asset Related Charges - Net
-
Note 5 - Supplementary Information
-
Note 6 - Income Taxes
-
Note 7 - Earnings Per Share of Common Stock - Not applicable for EIDP
-
Note 8 - Accounts and Notes Receivable - Net
-
Note 9 - Inventories
-
Note 10 - Other Intangible Assets
-
Note 11 - Short-Term Borrowings, Long-Term Debt and Available Credit Facilities
-
Note 12 - Commitments and Contingent Liabilities
-
Note 13 - Stockholders’ Equity
-
Note 14 - Pension Plans and Other Post Employment Benefits
-
Note 15 - Financial Instruments
-
Note 16 - Fair Value Measurements
-
Note 17 - Segment Information
-
Note 18 - Subsequent Events
NOTE 2 - RELATED PARTY TRANSACTIONS
Transactions with Corteva
EIDP and Corteva, including certain consolidated subsidiaries (collectively the “Participating Companies”), are party to a physical cash pooling arrangement which facilitates the management of the cash and liquidity needs of the Participating Companies.
For the three and nine months ended September 30, 2026, EIDP declared cash dividends to Corteva, Inc. amounting to $118 million and $745 million, respectively. EIDP paid dividends of $129 million and $870 million respectively, to Corteva, Inc. during the three and nine months ended September 30, 2026. For the three and nine months ended September 30, 2025, EIDP declared cash dividends to Corteva, Inc. amounting to $732 million and $1,620 million, respectively, of which $372 million and $1,260 million, respectively, were paid to Corteva, Inc. during the periods.
As of September 30, 2026, December 31, 2025 and September 30, 2025, EIDP had dividends payable to Corteva, Inc. of $8 million, $133 million and $360 million, respectively.
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
As of September 30, 2026, December 31, 2025 and September 30, 2025, EIDP had payables to Corteva, Inc. of $22 million, $27 million and $17 million included in accrued and other current liabilities, respectively, and $105 million, $154 million and $145 million included in other noncurrent obligations, respectively, in the interim Consolidated Balance Sheets related to Corteva’s indemnification liabilities to Dow and DuPont per the Corteva Separation Agreements (refer to the section entitled “Guarantees” of Note 12 - Commitments and Contingent Liabilities, to the interim Corteva Consolidated Financial Statements, for further details of the Corteva Separation Agreements).